4.7 Article

Risk and outcomes of COVID-19 in patients with multiple sclerosis

Journal

EUROPEAN JOURNAL OF NEUROLOGY
Volume 28, Issue 11, Pages 3712-3721

Publisher

WILEY
DOI: 10.1111/ene.14990

Keywords

COVID-19; incidence; multiple sclerosis; severe acute respiratory syndrome coronavirus 2; Spain

Funding

  1. Merck Spain

Ask authors/readers for more resources

This study found that patients with multiple sclerosis do not have a higher risk of SARS-CoV-2 infection or severe COVID-19 outcomes compared to the general population, but they do have higher hospitalization rates. In the study, males with MS had higher incidence rates and risk of hospitalization than females.
Background and purpose Limited information is available on incidence and outcomes of COVID-19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS-CoV-2 infection and COVID-19-related outcomes in patients with MS, and compared these with the general population. Methods A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit admission, and death in patients with MS and COVID-19. National government outcomes and seroprevalence data were used for comparison. The study was conducted at 14 specialist MS treatment centers in Madrid, Spain, between February and May 2020. Results Two-hundred nineteen patients were included in the registry, 51 of whom were hospitalized with COVID-19. The mean age +/- standard deviation was 45.3 +/- 12.4 years, and the mean duration of MS was 11.9 +/- 8.9 years. The infection incidence rate was lower in patients with MS than the general population (adjusted incidence rate ratio = 0.78, 95% confidence interval [CI] = 0.70-0.80), but hospitalization rates were higher (relative risk = 5.03, 95% CI = 3.76-6.62). Disease severity was generally low, with only one admission to an intensive care unit and five deaths. Males with MS had higher incidence rates and risk of hospitalization than females. No association was found between the use of any disease-modifying treatment and hospitalization risk. Conclusions Patients with MS do not appear to have greater risks of SARS-CoV-2 infection or severe COVID-19 outcomes compared with the general population. The decision to start or continue disease-modifying treatment should be based on a careful risk-benefit assessment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available